Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (527)	11/12/1998 11:52:00 AM
From: jopawa	Respond to of 2539

Anthony, I lifted this from thestreet.com today, their bio/drug reporter Eisienger gives some interesting takes on the industry. As a courtesy to them, if you are interested they have a 2 week free trial. John Back to Superaspirin Monsanto's (MTC:NYSE) Searle unit had more data on Celebrex, the superaspirin that is regarded as one of the next billion-dollar drugs. Merck's (MRK:NYSE) Vioxx is the other. The story of the COX-2 inhibitors, or superaspirins, is that they kill pain as well as other nonsteroidal anti-inflammatory drugs, but they don't cause the gastrointestinal bleeding that kills several thousand people each year. In the study presented Wednesday afternoon, Celebrex caused four stomach ulcers out of 212 patients, compared with 15 of 218 patients in the control group. The rate of upset stomach and abdominal pain wasn't starkly different between groups. Initially, Wall Street analysts think that the drug will be used for chronic pain and not by the weekend warriors who sprain their ankles and go to the hospital. But that still means big numbers, according to analysts.